Cover Image

Tyrphostin AG1478 inhibits encephalomyocarditis virus and hepatitis C virus by targeting phosphatidylinositol 4-Kinase IIIα

Encephalomyocarditis virus (EMCV), like hepatitis C virus (HCV), requires phosphatidylinositol 4-kinase IIIα (PI4KA) for genome replication. Here, we demonstrate that tyrphostin AG1478, a known epidermal growth factor receptor (EGFR) inhibitor, also inhibits PI4KA activity, both in vitro and in cell...

Full description

Saved in:
Bibliographic Details
Main Authors: Dorobantu, Cristina M. (Author) , Harak, Christian (Author) , Klein, Rahel (Author) , Linden, Lonneke van der (Author) , Strating, Jeroen R. P. M. (Author) , Schaar, Hilde M. van der (Author) , Lohmann, Volker (Author) , Kuppeveld, Frank J. M. van (Author)
Format: Article (Journal)
Language:English
Published: 1 August 2016
In: Antimicrobial agents and chemotherapy
Year: 2016, Volume: 60, Issue: 10, Pages: 6402-6406
ISSN:1098-6596
DOI:10.1128/AAC.01331-16
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1128/AAC.01331-16
Verlag, lizenzpflichtig, Volltext: https://aac.asm.org/content/60/10/6402
Get full text
Author Notes:Cristina M. Dorobantu, Christian Harak, Rahel Klein, Lonneke van der Linden, Jeroen R.P.M. Strating, Hilde M. van der Schaar, Volker Lohmann, Frank J.M. van Kuppeveld
Description
Summary:Encephalomyocarditis virus (EMCV), like hepatitis C virus (HCV), requires phosphatidylinositol 4-kinase IIIα (PI4KA) for genome replication. Here, we demonstrate that tyrphostin AG1478, a known epidermal growth factor receptor (EGFR) inhibitor, also inhibits PI4KA activity, both in vitro and in cells. AG1478 impaired replication of EMCV and HCV but not that of an EMCV mutant previously shown to escape PI4KA inhibition. This work uncovers novel cellular and antiviral properties of AG1478, a compound previously regarded only as a cancer chemotherapy agent.
Item Description:Gesehen am 24.04.2020
Physical Description:Online Resource
ISSN:1098-6596
DOI:10.1128/AAC.01331-16

Similar Items